Abstract 1843
Background
There are limitations in the prognosis stratification of stage III colon cancer patients using only the T and N stages, while other factors are unsure to be equally important. This study aimed to prove the prognostic importance of postoperative carcinoembryonic antigen (CEA) and stratify patients with stage III colon cancer more accurately by building a prognostic model combining CEA.
Methods
This was a retrospective cohort study. Patients with colon cancer who had CEA recorded within 100 days after resection at the centers from 2006 to 2017 were identified. The data included three different cancer centers in China: one training set and two validation sets, which were collected and analyzed in 2018. Postoperative CEA, T stage and N stage were combined to build the prognostic model, and patients with stage III colon cancer were divided into the high-risk group and the low-risk group. Harrell’s C-statistics, and net reclassification improvement (NRI) were used to assess the model performance. The disease-free survival (DFS) was compared between the high-risk group and the low-risk groups by the log-rank test.
Results
Among patients with elevated postoperative CEA, we found that CEA tested within 20 days (early test group) after resection was not reliable, since DFS of the early test group was higher than that of the delayed test group (p = 0.006). So, 834 patients with stage III disease which had CEA data for 21-100 days after resection were analyzed. In the training set, C-index for the model (combining T stage, N stage and postoperative CEA) was 0.74. Patients with elevated postoperative CEA, T4b, N2b or T4aN2a were classified as the high-risk group, with 3-year DFS of 55.8%, which was lower than the value of 86.0% in the low-risk group [hazard ratio (HR), 4.03; 95% CI, 2.49-6.54; p < 0.001]. When compared to the TNM model, this new model achieved a 10% NRI. These results were confirmed in the validation sets.
Conclusions
Patients with stage III colon cancer could be stratified much more accurately with the prognostic model combining T stage, N stage and postoperative CEA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Harbin Medical University Cancer Hospital Preeminence Youth Fund (JCQN2019-04).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4413 - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Presenter: Ghassan Abou-Alfa
Session: Poster Display session 2
Resources:
Abstract
4710 - Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Lorenza Rimassa
Session: Poster Display session 2
Resources:
Abstract
5509 - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)
Presenter: Li-Tzong Chen
Session: Poster Display session 2
Resources:
Abstract
1463 - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Presenter: Sylvie Lorenzen
Session: Poster Display session 2
Resources:
Abstract
2392 - GLOW: Randomized Phase 3 Study of Zolbetuximab + CAPOX Compared With Placebo + CAPOX as First-line Treatment of Patients With CLD18.2⁺/HER2⁻ Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Manish Shah
Session: Poster Display session 2
Resources:
Abstract
5217 - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial
Presenter: Rosine Guimbaud
Session: Poster Display session 2
Resources:
Abstract
1726 - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
Presenter: Kenro Hirata
Session: Poster Display session 2
Resources:
Abstract
2279 - FRONTiER: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Presenter: Shun Yamamoto
Session: Poster Display session 2
Resources:
Abstract
4912 - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Jiafu Ji
Session: Poster Display session 2
Resources:
Abstract
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract